{"id":"W1480235848","doi":"10.1371/journal.pone.0133133","title":"Bevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial","year":2015,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia","funders":"Fudan University; National Natural Science Foundation of China","keywords":"Bevacizumab; Medicine; Regimen; Leukopenia; Internal medicine; Metastatic breast cancer; Neutropenia; Oxaliplatin; Adverse effect; Anemia; Phases of clinical research; Progression-free survival; Gastroenterology; Febrile neutropenia; Chemotherapy regimen; Oncology; Breast cancer; Chemotherapy; Surgery; Colorectal cancer; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009923285,0.001029933,0.00152235,0.0003081876,0.0002726811,0.0007483702,0.0006363113,0.0009154036,0.002198783],"category_scores_gemma":[0.0005722372,0.0004157814,0.0009248415,0.0003489291,0.0005170001,0.0004795571,0.0002773868,0.001682621,0.0003869975],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006770355,"about_ca_system_score_gemma":0.0009539075,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009696541,"about_ca_topic_score_gemma":0.002843144,"domain_scores_codex":[0.9997895,0.00009555407,0.00001201604,0.00003452775,0.00002400424,0.00004439526],"domain_scores_gemma":[0.999632,0.00004510139,0.00008231031,0.00002112594,0.00002209959,0.0001973718],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8013103,0.04800048,0.00568942,0.0009618744,0.002015619,0.000241124,0.0001847847,0.002262401,0.02810434,0.0001677005,0.002876416,0.1081856],"study_design_scores_gemma":[0.7087939,0.2754985,0.009946821,0.00005273651,0.0005343329,0.0002121733,0.00002980727,0.001581205,0.001315705,0.000106745,0.001903337,0.00002485169],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9937309,0.003004498,0.0002677325,0.0003355684,0.0001050606,0.001268783,0.0002832028,0.00005025341,0.000953981],"genre_scores_gemma":[0.9916759,0.002682909,0.0009976056,0.0007095095,0.0002200903,0.001423886,0.001044282,0.00001351757,0.001232295],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002198783,"threshold_uncertainty_score":0.00735569,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1413053886415905,"score_gpt":0.3873994333068337,"score_spread":0.2460940446652432,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}